Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
Cancers · 19.10.2023 · 15 (20) · 5047
DOI: 10.3390/cancers15205047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.10.2023. Verfasst von Thi Khanh Le und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche en Cancérologie de Marseille-CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, 13009 Marseille, France. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INSERM, Association pour la Recherche sur les Tumeurs de la Prostate (ARTP), La Fondation A*Midex -2021 AAP Interdisciplinarité.
Abstract (Originalsprache)
Prostate cancer (PC) is the second most common cancer in men worldwide. Despite recent advances in diagnosis and treatment, castration-resistant prostate cancer (CRPC) remains a significant medical challenge. Prostate cancer cells can develop mechanisms to resist androgen deprivation therapy, such as AR overexpression, AR mutations, alterations in AR coregulators, increased steroidogenic signaling pathways, outlaw pathways, and bypass pathways. Various treatment options for CRPC exist, including androgen deprivation therapy, chemotherapy, immunotherapy, localized or systemic therapeutic radiation, and PARP inhibitors. However, more research is needed to combat CRPC effectively. Further investigation into the underlying mechanisms of the disease and the development of new therapeutic strategies will be crucial in improving patient outcomes. The present work summarizes the current knowledge regarding the underlying mechanisms that promote CRPC, including both AR-dependent and independent pathways. Additionally, we provide an overview of the currently approved therapeutic options for CRPC, with special emphasis on chemotherapy, radiation therapy, immunotherapy, PARP inhibitors, and potential combination strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre de Recherche en Cancérologie de Marseille-CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, 13009 Marseille, France.
- European Center for Research in Medical Imaging (CERIMED), Aix-Marseille University, 13005 Marseille, France.
- Vietnam Academy of Science and Technology (VAST), University of Science and Technology of Hanoi (USTH), Hanoi 10000, Vietnam.
- Department of Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, 13005 Marseille, France.
- Department of Urology AP-HM, Aix-Marseille University, 13005 Marseille, France.
- Faculté de Médecine Timone, INSERM, MMG, U1251, Aix-Marseille University, 13385 Marseille, France.
ORCID-Profile: Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Michael Baboudjian, Palma Rocchi
Förderung
- INSERM
- Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)
- La Fondation A*Midex -2021 AAP Interdisciplinarité
- ITMO Cancer
- France Excellence scholarship
Zitieren
APA
Le, T. K., Duong, Q. H., Baylot, V., Fargette, C., Baboudjian, M., Colleaux, L., Taïeb, D., & Rocchi, P. (2023). Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. Cancers, 15(20), 5047. https://doi.org/10.3390/cancers15205047
Vancouver
Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, et al. Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. Cancers. 2023;15(20):5047. doi:10.3390/cancers15205047
BibTeX
@article{Le2023,
author = {Le, Thi Khanh and Duong, Quang Hieu and Baylot, Virginie and Fargette, Christelle and Baboudjian, Michael and Colleaux, Laurence and Taïeb, David and Rocchi, Palma},
title = {Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments},
journal = {Cancers},
year = {2023},
volume = {15},
number = {20},
pages = {5047},
doi = {10.3390/cancers15205047}
}
EUVIMED